Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Biohaven’s valuation has dropped from $3.9B to $1.42B, but no revenue and high cash burn still limit its appeal. Read why ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Study Design: This interventional study is randomized and follows a parallel assignment model. It is double-blind, meaning neither participants nor the care providers, investigators, or outcome ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) ('Ascentage Pharma” or the 'Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, ...

Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so.

Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.

The Dow Jones Industrial Average climbed on Thursday (July 10) as investors brushed aside concerns over new tariff ...

Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) ('Ascentage” or the 'Company”), a global ...

Stock prices in Europe were largely higher on Tuesday, setting aside the tariff worries that kept enthusiasm to a minimum at the start of the week. London's FTSE 100 tread water, but not after ...